Key Drivers
- Strong Liquidity
- Persistent Cash Burn
- Equity Dilution
AIAI Summary
Trevi is now a well-funded, high-risk clinical catalyst play—its $319M cash runway reduces near-term dilution through 2027, but valuation hinges almost entirely on Phase 3 OCEAN data validating Haduvio in IPF cough; investors should view weakness as an opportunity only if they can tolerate binary trial and commercialization risk.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Persistent Cash Burn
- •Equity Dilution
TRVI has ample liquidity and minimal debt, but investors should weigh ongoing losses, heavy cash burn, dilution, and a valuation well above book value.
Price Behavior
Key Price Behavior Insights:
- •Persistent selling
- •Oversold RSI
- •Failed rebound
TRVI remains in a last-month downtrend near $14.95; watch $15.00 support for a bounce, but a break lower is bearish unless price reclaims $16.00.
Failed one-day rebound on 2026-09-17 signaled continued selling pressure
Sentiment & News
Key News Insights:
- •Pivotal Trial Progress
- •ERS Data Presentation
- •Platform Expansion
Trevi is advancing Haduvio through pivotal chronic-cough development, supported by positive Phase 2 data and upcoming clinical presentations.
Continued clinical momentum and investor outreach could support positive sentiment toward Trevi Therapeutics
Similar Companies in Healthcare
Other companies in the same sector with AI ratings